Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Metastatic Breast Cancer|Advanced Breast Cancer|HER2/Neu-positive Breast Cancer
Interventions: DRUG: Capecitabine|DRUG: Lapatinib
Sponsor: Rutgers, The State University of New Jersey
Collaborators: National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey